California State Teachers Retirement System Acquires 38,431 Shares of Theravance Biopharma, Inc. $TBPH

California State Teachers Retirement System increased its holdings in Theravance Biopharma, Inc. (NASDAQ:TBPH) by 1,649.4% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 40,761 shares of the biopharmaceutical company’s stock after acquiring an additional 38,431 shares during the quarter. California State Teachers Retirement System’s holdings in Theravance Biopharma were worth $662,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also added to or reduced their stakes in the stock. Arrowstreet Capital Limited Partnership purchased a new position in Theravance Biopharma during the 3rd quarter valued at $10,611,000. Pacer Advisors Inc. bought a new position in Theravance Biopharma in the 4th quarter worth $6,342,000. Janus Henderson Group PLC lifted its position in shares of Theravance Biopharma by 214.8% in the 4th quarter. Janus Henderson Group PLC now owns 400,496 shares of the biopharmaceutical company’s stock worth $7,493,000 after purchasing an additional 273,288 shares during the period. Two Sigma Investments LP lifted its position in shares of Theravance Biopharma by 1,199.9% in the 3rd quarter. Two Sigma Investments LP now owns 231,272 shares of the biopharmaceutical company’s stock worth $3,377,000 after purchasing an additional 213,480 shares during the period. Finally, HRT Financial LP boosted its stake in shares of Theravance Biopharma by 892.8% during the 4th quarter. HRT Financial LP now owns 232,852 shares of the biopharmaceutical company’s stock valued at $4,356,000 after purchasing an additional 209,397 shares in the last quarter. Institutional investors own 99.10% of the company’s stock.

Theravance Biopharma Price Performance

NASDAQ:TBPH opened at $16.97 on Friday. The firm has a market capitalization of $881.08 million, a P/E ratio of 16.80 and a beta of 0.19. Theravance Biopharma, Inc. has a one year low of $12.78 and a one year high of $21.03. The company’s 50-day simple moving average is $16.86 and its 200 day simple moving average is $16.81.

Theravance Biopharma (NASDAQ:TBPH) last announced its earnings results on Monday, August 10th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.18). Theravance Biopharma had a net margin of 51.58% and a negative return on equity of 0.77%. The business had revenue of $20.73 million for the quarter, compared to the consensus estimate of $22.49 million. On average, equities research analysts expect that Theravance Biopharma, Inc. will post 1.56 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts recently issued reports on the stock. BTIG Research cut shares of Theravance Biopharma from a “buy” rating to a “neutral” rating in a research report on Monday, June 29th. Wall Street Zen lowered shares of Theravance Biopharma from a “buy” rating to a “hold” rating in a report on Saturday, May 16th. HC Wainwright cut Theravance Biopharma from a “buy” rating to a “neutral” rating and lifted their price objective for the company from $15.00 to $17.00 in a research report on Tuesday, July 7th. Zacks Research upgraded Theravance Biopharma from a “hold” rating to a “strong-buy” rating in a report on Friday, August 7th. Finally, JonesTrading lowered Theravance Biopharma from a “buy” rating to a “hold” rating in a research report on Monday, June 29th. One research analyst has rated the stock with a Strong Buy rating and seven have issued a Hold rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $19.40.

Insider Activity at Theravance Biopharma

In related news, SVP Rhonda Farnum sold 13,314 shares of the firm’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $16.39, for a total transaction of $218,216.46. Following the completion of the transaction, the senior vice president owned 232,457 shares of the company’s stock, valued at $3,809,970.23. This trade represents a 5.42% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, major shareholder Eli Samaha sold 37,799 shares of the firm’s stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $17.00, for a total value of $642,583.00. Following the transaction, the insider directly owned 9,174,453 shares of the company’s stock, valued at approximately $155,965,701. This trade represents a 0.41% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 350,011 shares of company stock worth $6,008,309 in the last 90 days. 7.65% of the stock is currently owned by company insiders.

Theravance Biopharma Company Profile

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.